Long-Term Follow-Up of 106 Multiple Sclerosis Patients Undergoing Interferon-β 1a or 1b Therapy: Predictive Factors of Thyroid Disease Development and Duration

• DOI: 10.1210/jc.2004-2326
• Publication Date: 2005-07-07T06:50:02Z
• Authors: N. Caraccio; A. Dardano; F. Manfredonia; L. Manca; L. Pasquali; A. Iudice; L. Murri; E. Ferrannini; F. Monzani
• Keywords: Adult; Male; Multiple Sclerosis; Time Factors; Thyroid Gland; Autoimmunity; Interferon-beta; Middle Aged; Thyroid Diseases; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Humans; Female; Interferon beta-1a; Follow-Up Studies; Interferon beta-1b

AbstractBackground: Conflicting data have been reported on the association between interferon (IFN)-β therapy of multiple sclerosis (MS) patients and thyroid disease development.Aims: The goals of this study are as follows: to assess the actual occurrence of thyroid dysfunction and autoimmunity during long-term IFN-β therapy; to establish the possible presence of predictive factors for thyroid dysfunction development and duration; and to suggest an effective follow-up protocol for patients receiving long-term IFN-β therapy.Study Protocol: A total of 106 MS patients (76 women) underwent IFN-β 1a or 1b therapy for up to 84 months (median, 42 months). Thyroid function and autoimmunity were assessed at baseline and every 3–6 months throughout the treatment course.Results: Baseline thyroid autoimmunity was detected in 8.5% of patients and hypothyroidism in 2.8%. Thyroid dysfunction (80% hypothyroidism, 92% subclinical, 56% transient) developed in 24% (68% with autoimmunity) of patients and autoimmunity in 22.7% (45.5% with dysfunction), without significant differences between the two cytokines; 68% of dysfunctions occurred within the first year. Autoimmunity emerged as the only predictive factor for dysfunction development (relative risk, 8.9), whereas sustained disease was significantly associated with male gender (P < 0.003).Conclusions: Both incident thyroid autoimmunity and dysfunction frequently occur in MS patients during IFN-β therapy, particularly within the first year of treatment. Thyroid dysfunction is generally subclinical and transient in over than half of cases; preexisting or incident autoimmunity emerged as the only significant predictive factor for thyroid dysfunction development. Thyroid function and autoimmunity assessment is mandatory within the first year of IFN-β therapy; thereafter, serum TSH measurement only in patients with thyroid disease could be sufficient.